Cargando…
MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib
Evading apoptosis is a cancer hallmark that remains a serious obstacle in current treatment approaches. Although proteasome inhibitors (PIs) have transformed management of multiple myeloma (MM), drug resistance emerges through induction of the aggresome+autophagy pathway as a compensatory protein cl...
Autores principales: | Jagannathan, S, Vad, N, Vallabhapurapu, S, Anderson, K C, Driscoll, J J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4360212/ https://www.ncbi.nlm.nih.gov/pubmed/25234165 http://dx.doi.org/10.1038/leu.2014.279 |
Ejemplares similares
-
Bortezomib induces AMPK-dependent autophagosome formation uncoupled from apoptosis in drug resistant cells
por: Jaganathan, Sajjeev, et al.
Publicado: (2014) -
Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma
por: Abdel Malek, Mohamed A.Y., et al.
Publicado: (2014) -
Chidamide epigenetically represses autophagy and exerts cooperative antimyeloma activity with bortezomib
por: Xu, Li, et al.
Publicado: (2020) -
ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5
por: Yang, Yan, et al.
Publicado: (2022) -
Autophagic sequestration of SQSTM1 disrupts the aggresome formation of ubiquitinated proteins during proteasome inhibition
por: Zhang, Chenliang, et al.
Publicado: (2022)